SCHEDULE: RTW Investments Boosts Exagen Stake to 7.7%

RTW Investments, LP and Roderick Wong, M.D. reported a 7.7% passive ownership stake in Exagen Inc., holding 1,696,866 common shares as of June 30, 2025.

Summary

• RTW Investments, LP and Roderick Wong, M.D. collectively reported beneficial ownership of 1,696,866 shares of Exagen Inc. Common Stock.
• This ownership represents 7.7% of Exagen Inc.'s outstanding common stock.
• The percentage is calculated based on 21,998,739 shares outstanding as of June 30, 2025, as reported in Exagen Inc.'s Quarterly Report on Form 10-Q filed on July 29, 2025.
• RTW Investments, LP, a Delaware limited partnership, acts as an investment adviser to certain funds (the "RTW Funds").
• Roderick Wong, M.D., a U.S. citizen, is the Managing Partner and Chief Investment Officer of RTW Investments, LP.
• Both reporting persons share voting and dispositive power over all 1,696,866 beneficially owned shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Exagen Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by RTW Investments, LP and Roderick Wong, M.D. in Exagen Inc., suggesting confidence in the company's long-term prospects from a notable institutional investor. The passive nature of the investment, however, limits direct influence on company operations.

Positives

• A significant passive investment by a prominent institutional investor like RTW Investments, LP, and its managing partner, Roderick Wong, M.D., signals confidence in Exagen Inc.'s long-term prospects.
• The 7.7% stake indicates a substantial commitment from a sophisticated investor, which can be viewed positively by the market.

Risks

• The filing is a passive ownership disclosure and does not detail specific operational or financial risks of Exagen Inc. itself.
• The reporting persons explicitly state that their investment is not for the purpose of changing or influencing control, meaning they will not actively intervene in company management or strategy.

Future Outlook

This filing is a disclosure of beneficial ownership by an institutional investor and does not contain forward-looking statements or guidance from Exagen Inc.'s management.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

Exagen Inc. operates in the biotechnology and diagnostics sector, focusing on autoimmune diseases. The investment by RTW Investments, a firm specializing in life sciences, aligns with typical investment patterns in this industry, where specialized funds often take significant stakes in promising companies.

Stakeholder Impact

• Shareholders may view the significant stake by a reputable investment firm as a positive signal, potentially increasing investor confidence and validating the company's trajectory.
• The passive nature of the investment means no immediate impact on company management or strategic direction is expected from these reporting persons.

Key Dates

Recommendation

The filing indicates a substantial passive stake by a prominent investment firm, suggesting a long-term view. While not an active endorsement for immediate purchase, it signals a vote of confidence from a sophisticated investor, making it a 'hold' for those already invested and a point of consideration for new investors.

Keywords

Exagen Inc., RTW Investments, Roderick Wong, beneficial ownership, Schedule 13G, common stock, passive investment, biotechnology, diagnostics